These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 32348828)
1. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. Eichenfield L; Hebert A; Gold LS; Cartwright M; Fragasso E; Moro L; Mazzetti A J Am Acad Dermatol; 2020 Aug; 83(2):477-485. PubMed ID: 32348828 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study. Mazzetti A; Moro L; Gerloni M; Cartwright M J Drugs Dermatol; 2019 Jun; 18(6):563. PubMed ID: 31251549 [TBL] [Abstract][Full Text] [Related]
4. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne. Mazzetti A; Moro L; Gerloni M; Cartwright M J Drugs Dermatol; 2019 Jun; 18(6):570. PubMed ID: 31251550 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris. Eichenfield LF; Hebert AA; Gold LS; Cartwright M; Moro L; Han J; Squittieri N; Mazzetti A J Drugs Dermatol; 2023 Aug; 22(8):810-816. PubMed ID: 37556524 [TBL] [Abstract][Full Text] [Related]
6. Clascoterone: First Approval. Dhillon S Drugs; 2020 Nov; 80(16):1745-1750. PubMed ID: 33030710 [TBL] [Abstract][Full Text] [Related]
7. Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone. Bhatia N; Eichenfield LF; Mazzetti A; Moro L; Squittieri N; Hebert AA J Drugs Dermatol; 2024 Jun; 23(6):433-437. PubMed ID: 38834220 [TBL] [Abstract][Full Text] [Related]
8. Clascoterone cream (1%) topical androgen receptor inhibitor for the treatment of acne in patients 12 years and older. Gold M Expert Rev Clin Immunol; 2021 Apr; 17(4):301-308. PubMed ID: 33616473 [TBL] [Abstract][Full Text] [Related]
9. Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne. Kalabalik-Hoganson J; Frey KM; Ozdener-Poyraz AE; Slugocki M Ann Pharmacother; 2021 Oct; 55(10):1290-1296. PubMed ID: 33533262 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials. Alkhodaidi ST; Al Hawsawi KA; Alkhudaidi IT; Magzoub D; Abu-Zaid A Dermatol Ther; 2021 Jan; 34(1):e14609. PubMed ID: 33258536 [TBL] [Abstract][Full Text] [Related]
11. Individual Article: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne. Peterson H; Kircik L; Armstrong AW J Drugs Dermatol; 2023 Jun; 22(6):SF350992s7-SF350992s14. PubMed ID: 37276168 [TBL] [Abstract][Full Text] [Related]
12. Clascoterone: a new topical anti-androgen for acne management. Santhosh P; George M Int J Dermatol; 2021 Dec; 60(12):1561-1565. PubMed ID: 34242398 [TBL] [Abstract][Full Text] [Related]
13. Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris. Eichenfield LF; Gold LS; Han J; Hebert AA; Mazzetti A; Moro L; Squittieri N; Thiboutot D J Drugs Dermatol; 2024 Jan; 23(1):1278-1283. PubMed ID: 38206145 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris. Hebert A; Eichenfield L; Thiboutot D; Stein Gold L; Vassileva S; Mihaylova Y; Cartwright M; Moro L; Fragasso E; Han J; Squittieri N; Mazzetti A J Drugs Dermatol; 2023 Feb; 22(2):174-181. PubMed ID: 36745367 [TBL] [Abstract][Full Text] [Related]
15. Clascoterone cream (Winlevi) for acne. Med Lett Drugs Ther; 2021 Dec; 63(1640):202-204. PubMed ID: 35100239 [No Abstract] [Full Text] [Related]
16. Topical Clascoterone: The First Novel Agent for Acne Vulgaris in 40 Years. Piszczatoski CR; Powell J Clin Ther; 2021 Oct; 43(10):1638-1644. PubMed ID: 34607697 [TBL] [Abstract][Full Text] [Related]
17. Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro. Rosette C; Agan FJ; Mazzetti A; Moro L; Gerloni M J Drugs Dermatol; 2019 May; 18(5):412-418. PubMed ID: 31141847 [TBL] [Abstract][Full Text] [Related]
18. Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist. Kircik LH Expert Opin Pharmacother; 2021 Sep; 22(13):1801-1806. PubMed ID: 33906537 [No Abstract] [Full Text] [Related]
19. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. Blume-Peytavi U; Fowler J; Kemény L; Draelos Z; Cook-Bolden F; Dirschka T; Eichenfield L; Graeber M; Ahmad F; Alió Saenz A; Rich P; Tanghetti E J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):166-173. PubMed ID: 31306527 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of in vitro Skin Permeation of Clascoterone From Clascoterone Topical Cream, 1% (w/w). Yang Y; Wang J; Wanasathop A; Niu M; Ghosh P; Zidan A; Gu J; Hunt R; Faustino P; Ashraf M; Xu X AAPS PharmSciTech; 2024 Aug; 25(6):186. PubMed ID: 39138712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]